Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease

International Reviews of Immunology

Volumn 31, Issue 5, 2012, Pages 410-427

  Ghosh, Nilanjan ^a   Chaki, Rituparna ^a   Mandal, Subhash C ^b  

^a Dr B C Roy College of Pharmacy and Allied Health Sciences   (India)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

Chemokine; Inflammatory bowel disease; Integrin; Lymphocyte trafficking; Monoclonal antibody; selectin

Indexed keywords

AGENTS USED IN INFLAMMATORY BOWEL DISEASE; AJM 300; ALICAFORSEN; CCX 282B; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INFLIXIMAB; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; MONOCLONAL ANTIBODY; NATALIZUMAB; PADGEM PROTEIN; PF 00547 659; PF 00547659; PREDNISONE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB; VERCIRNON;

ARTICLE; CELL HOMING; CELL MIGRATION; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; HUMAN; INTESTINE MUCOSA; INTRACELLULAR SIGNALING; LEUKOCYTE; LEUKOCYTE ROLLING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SHORT FORM 36; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL ADHESION MOLECULES; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION; HUMANS; INFLAMMATORY BOWEL DISEASES; INTEGRIN ALPHA4; LYMPHOCYTES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; RISK ASSESSMENT;

EID: 84867823546     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.690794     Document Type: Article

References (90)

1. Assche G, Emerging drugs to treat Crohn's disease. Expert Opin Emerging Drugs. 2007;12:49-59.
2. Roda G, Sartini A, Zambon E, et al. Intestinal epithelial cells in inflammatory bowel diseases.World J Gastroenterol. 2010;16:4264-4271.
3. Dryden GW Jr. Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther. 2009;9:967-974.
4. Rodr'iguez-Reyna TS, Mart'inez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease.World J Gastroenterol. 2009;15:5517-5524.
5. Wahli W. A gut feeling of the PXR, PPAR and NF-kappaB connection. J Intern Med. 2008;263:613-619.
6. Actis GC, Rosina F, Mackay IR. Inflammatory bowel disease: beyond the boundaries of the bowel. Expert Rev Gastroenterol Hepatol. 2011;5:401-410.
7. Ghosh N, Chaki R, Mandal V, et al. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases. Int Rev Immunol. 2010; 29:4-37
8. Raza A, Yousaf W, Giannella R, et al.Th17 cells: Interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev Clin Immunol. 2012;8:161-168.
9. Nielsen OH, Seidelin JB,Munck LK, et al. Use of biological molecules in the treatment of inflammatory bowel disease. J InternMed. 2011;270:15-28.
10. Fiorino G, Correale C, Fries W, Repici A, Malesci A, Danese S. Leukocyte traffic control: A novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:567-572.
11. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: Vascular adhesion molecules. FASEB J. 1995;9:866-873.
12. Yonekawa K, Harlan JM. Targeting leukocyte integrins in human diseases. J Leukoc Biol. 2005;77:129-140.
13. Vestweber D. Ligand-specificity of the selectins. J Cell Biochem. 1996;61:585-591.
14. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev. 1999;79:181-213.
15. Walzog B, Gaehtgens P. Adhesion molecules: The path to a new understanding of acute inflammation. News Physiol Sci. 2000;15:107-113.
16. von Andrian UH,Hasslen SR, Nelson RD, et al. A central role for microvillous receptor presentation in leukocyte adhesion under flow. Cell. 1995;82:989-999.
17. Buscher K, Riese SB, Shakibaei M, et al. The transmembrane domains of L-selectin and CD44 regulate receptor cell surface positioning and leukocyte adhesion under flow. J Biol Chem. 2010;285:13490-13497.
18. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev. 1999;79:181-213.
19. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859-873.
20. Laroux FS, Pavlick KP,Wolf RE, et al.Dysregulation of intestinalmucosal immunity: Implications in inflammatory bowel disease. News Physiol Sci. 2001;16:272-277.
21. Van Assche G, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases, I: Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288(2):G169-G174.
22. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics. 2009;3:77-97.
23. Akiyama SK. Integrins in cell adhesion and signaling. HumCell. 1996;9:181-186.
24. Campbell ID,Humphries MJ. Integrin structure, activation, and interactions. Cold SpringHarb Perspect Biol. 2011;3:pii: A004994
25. Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:239-258.
26. Hughes PE, Diaz-Gonzalez F, Leong L, et al. Breaking the integrin hinge: A defined structural constraint regulates integrin signaling. J Biol Chem. 1996;271:6571-6574.
27. Arnaout MA. Integrin structure: New twists and turns in dynamic cell adhesion. Immunol Rev. 2002;186:125-140.
28. Garc'ia AJ, Takagi J, Boettiger D. Two-stage activation for alpha5beta1 integrin binding to surfaceadsorbed fibronectin. J Biol Chem. 1998;273:34710-34715.
29. Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. CurrMolMed. 2009;9:836-50.
30. Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: Targeting alpha-4 integrin. Am J Gastroenterol. 2003;98:2372-2382.
31. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest. 1994;94:1722-1728.
32. Zabel BA, Agace WW, Campbell JJ, et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J ExpMed. 1999;190:1241-1256.
33. Johansson-Lindbom B, Svensson M, Wurbel MA, et al. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): Requirement for GALT dendritic cells and adjuvant. J Exp Med. 2003;198:963-969.
34. Papadakis KA. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep. 2004;4:83-89.
35. Mora JR, BonoMR,Manjunath N, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature. 2003;424:88-93.
36. Bridges LC, Tani PH, Hanson KR, et al. The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1. J Biol Chem. 2002;277:3784-3792.
37. Li Z, Calzada MJ, Sipes JM, et al. Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol. 2002;157:509-519.
38. Yakubenko VP, Lobb RR, Plow EF, et al. Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res. 2000;260:73-84.
39. Weber C, Fraemohs L, Dejana E.The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol. 2007;7:467-477.
40. MandellKJ,BabbinBA,Nusrat A, et al. Junctional adhesionmolecule 1 regulates epithelial cell morphology through effects on beta1 integrins and Rap1 activity. J Biol Chem. 2005;280:11665-11674.
41. Ludwig RJ, Hardt K, Hatting M, et al. Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin. Immunology. 2009;128:196-205.
42. Saunders KE, Shen Z,Dewhirst FE, et al.Novel intestinalHelicobacter species isolated fromcottontop tamarins (Saguinus oedipus) with chronic colitis. J ClinMicrobiol. 1999;37:146-151.
43. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest. 1993;92:372-380.
44. Hamamoto N, Maemura K, Hirata I, et al. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesionmolecules (endothelial leucocyte adhesionmolecule-1 (ELAM-1) or intercellular adhesionmolecule-1 (ICAM-1)). Clin Exp Immunol. 1999;117:462-468.
45. McNamee EN, Wermers JD, Masterson JC, et al. Novel model of TH2-polarized chronic ileitis: The SAMP1mouse. Inflamm Bowel Dis. 2010;16:743-752.
46. Rivera-Nieves J, Olson T, Bamias G, et al. L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J Immunol. 2005;174:2343-2352.
47. Matsuzaki K, Tsuzuki Y,Matsunaga H, et al. In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinalmucosa of SAMP1/Yit mice by the inhibition ofMAdCAM-1. Clin Exp Immunol. 2005;140:22-31.
48. Inoue T, Tsuzuki Y, Matsuzaki K, et al. Blockade of PSGL-1 attenuates CD14+ monocytic cell recruitment in intestinal mucosa and ameliorates ileitis in SAMP1/Yit mice. J Leukoc Biol. 2005;77: 287-95.
49. Siegmund B. Targeted therapies in inflammatory bowel disease. Dig Dis. 2009;27:465-469.
50. Dryden GW Jr. Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther. 2009;9:967-974.
51. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268-274.
52. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
53. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl JMed. 2005;353:1912-1925.
54. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology. 2007;132:1672-1683.
55. Dudley-Brown S,Nag A, Cullinan C, et al.Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. Gastroenterol Nurs. 2009;32:327-339.
56. Feagan BG, Sandborn WJ, Hass S, et al. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol. 2007;102:2737-2746.
57. Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007;13:2-11.
58. Richardson-Burns SM, Kleinschmidt-DeMasters BK, DeBiasi RL, et al. Progressive multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central nervous system of patients with and without AIDS. Arch Neurol. 2002;59:1930-1936.
59. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressivemultifocal leukoencephalopathy. N Engl JMed. 2006;354:924-933.
60. Tilg H, Kaser A. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs. 2010;11:1295-1304.
61. Feagan BG, Greenberg GR,Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl JMed. 2005;352:2499-2507.
62. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6: 1370-1377.
63. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3:76-99.
64. Barish CF. Alicaforsen therapy in inflammatory bowel disease. Expert Opin Biol Ther. 2005;5:1387-1391.
65. Henry SP, Templin MV, Gillett N, et al. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol. 1999b;27: 95-100.
66. Yacyshyn B, Bowen-Yacyshyn MB, Shanahan W. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease. Curr OpinMolTher. 1999;1:332-335.
67. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998;114:1133-1142.
68. vanDeventer SJ, Tami JA,WedelMK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 2004;53:1646-1651.
69. van Deventer SJ, Wedel MK, Baker BF, et al. A phase II dose ranging, double-blind, placebocontrolled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate leftsided ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1415-1425.
70. Miner PB Jr, Geary RS, Matson J, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1427-1434.
71. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut. 2002;51:30-36.
72. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study. Gut. 2011;60:1068-1075.
73. Ten Hove T,The Olle F, Berkhout M, et al. Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease. J Leukoc Biol. 2004;75:1010-1015.
74. Stefanich EG, Danilenko DM, Wang H, et al. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011;162:1855-1870.
75. Rutgeerts Paul J, Fedorak Richard N, Hommes Daniel W, et al. A Phase I study of rHuMab Beta7 in moderate to severe ulcerative colitis (UC). Gastroenterology. 2011; 140:S1, 125
76. WurbelMA,Philippe JM,NguyenC, et al.ThechemokineTECKis expressedby thymic and intestinal epithelial cells and attracts double- And single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol. 2000;30:262-271.
77. Hosoe N, Miura S, Watanabe C, et al. Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa. Am J Physiol Gastrointest Liver Physiol. 2004;286:G458-G466.
78. Villablanca EJ, Cassani B, von Andrian UH, et al. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology. 2011;140:1776-1784.
79. Kunkel EJ, Campbell DJ, Butcher EC. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation. 2003;10:313-323.
80. Hart AL, Ng SC,Mann E, et al. Homing of immune cells: Role in homeostasis and intestinal inflammation. Inflamm Bowel Dis. 2010;16:1969-1977.
81. Miles A, Liaskou E, Eksteen B, et al. CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes toMAdCAM-1 under shear flow. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1257-G1267.
82. WaltersMJ,Wang Y, Lai N, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol ExpTher. 2010;335:61-69.
83. Bekker P, Keshav S, Johnson D, et al. PROTECT-1maintenance phase study results demonstrate efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in Crohn's disease. Advances in Inflammatory Bowel Diseases; Crohn's & Colitis Foundation's Clinical & Research Conference, Hollywood, FL. Inflammatory Bowel Diseases. 2009; 15:S2Abstract #P-0022
84. Bekker P, Petryka R, Van'ask T, et al. PROTECT-1, a prospective randomized oral therapy evaluation of CCX282-B (Trafficet-EN) in Crohn's disease trial. CCFA National Research and Clinical Conference, 6th Annual Advances in the Inflammatory Bowel Diseases, Dec. 6-9, Aventura, Florida. Inflammatory Bowel Diseases. 2007; 14:S11Abstract #P-003
85. TakazoeM,WatanabeM, Kawaguchi T, et al. S1066 oral alpha-4 integrin inhibitor (AJM300) in patientswith active Crohn's disease: A randomized, double-blind, placebo-controlled trial.Gastroenterology. 2009;136:A-181.
86. Lafrenie RM, Buckner CA, BewickMA. Cell adhesion and cancer: Is there a potential for therapeutic intervention? Expert OpinTher Targets. 2007;11:727-731.
87. Podar K, Zimmerhackl A, FulcinitiM, et al.Theselective adhesionmolecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: Therapeutic implications. Br J Haematol. 2011;155:438-448.
88. Giovannoni G. Promising emerging therapies formultiple sclerosis. Neurol Clin. 2011;29:435-448.
89. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsingmultiple sclerosis. N Engl JMed. 2006; 354:899-910.
90. Miller DH, Soon D, Fernando KT, et al.MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68:1390-1401.